International Stem Cell Corp. is inching closer to bringing its stem cell therapy for Parkinson's to the FDA in hopes of eventually reversing the disease's symptoms in people.
A new discovery that explains how the body's immune system makes a potent antibody that blocks HIV infection may be an important step toward developing a vaccine against the virus.
Researchers think they've discovered why previous efforts at targeting the enzyme LTA4 hydrolase, a key player in the body's inflammatory response, have failed and produced a new molecule that may prove more successful.
An experimental antiviral compound developed by BioCryst Pharmaceuticals and the U.S. Army Medical Research Institute of Infectious Diseases provided complete protection in monkeys against Marburg virus and Ebola, two highly virulent pathogens with no effective treatments.
A supplement that activates a protein involved in metabolic balance showed an extension in lifespan and improvement in the overall health of mice, according to a new study.
Increased brain cell activity seems to boost levels of the protein tau, a hallmark of Alzheimer's disease, according to researchers. The link could help advance efforts to treat Alzheimer's disease and other neurodegenerative disorders.
The NIH has added a huge amount of medical data--from a diverse group of more than 78,000 people with an average age of 63--to Genetic Epidemiology Research on Aging, one of the nation's largest and most diverse genomics projects.
The Department of Defense has selected Denmark's Bavarian Nordic to develop a vaccine against two potential biological pathogens deemed to be threats to national security.
A new vaccine developed by German researchers may be effective against a certain type of skin cancer in organ transplant patients caused by papillomavirus.
Researchers have found a way to transform skin cells into fully functioning mature liver cells that grow on their own after being transplanted into mice.
Last month AstraZeneca said it is shuttering an Indian research site as it moves away from neglected diseases to focus on areas with more potential for growth. The move is a hit to global tuberculosis R&D, which received $10 million from AstraZeneca in 2012.
Some say the recent allegations about a potential stem cell breakthrough unveiled in January by a major Japanese research institution represent a larger problem of irreproducibility in early science research. But others, like Edward Ahn, managing director and chief science officer of Cambridge, MA-based MedCap Advisors, think we shouldn't jump to conclusions quite yet.
The Sunnyvale, CA-based Parkinson's Institute and Clinical Center and pharma company Berg are partnering to identify potential biomarkers to help diagnose and treat Parkinson's disease.
An experimental gene therapy developed by investigators at the Icahn School of Medicine at Mount Sinai successfully regenerated heart muscle in pigs following a heart attack.
A protein previously known for other functions has also been found to act as a switch that decides whether an immature neural cell stays in a stem cell-like state or differentiates into a functional neuron.
A protein known to be part of a complex communications network within the cell has also been found to be associated with important processes involved in cancer and diabetes.
In the Journal of Medicinal Chemistry, scientists report that they've found a new compound that may offer protection against Parkinson's disease.
Israel's BioLineRx has unveiled positive preclinical data for its experimental treatment for chronic myeloid leukemia, a progressive blood and bone marrow cancer.
Resistance to antibacterials is fast becoming one of the most urgent public health problems, especially since the pipeline for new antibiotics largely has dried after Big Pharma's retreat from the field in recent years.
AstraZeneca's biologics arm MedImmune has tapped the University of California, San Francisco for a three-year drug discovery and development partnership.